Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure  by Liu, Yun-He et al.
PR
a
E
R
Y
O
D
M
d
s
c
M
A
k
a
H
a
p
c
i
l
l
M
H
2
Journal of the American College of Cardiology Vol. 43, No. 8, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.11.044RECLINICAL STUDIES
ole of Angiotensin II Type 2 Receptors
nd Kinins in the Cardioprotective
ffect of Angiotensin II Type 1
eceptor Antagonists in Rats With Heart Failure
un-He Liu, MD,* Xiao-Ping Yang, MD,* Edward G. Shesely, PHD,* Steadman S. Sankey, PHD,†
scar A. Carretero, MD*
etroit, Michigan
OBJECTIVES We studied the role of angiotensin II type 2 (AT2) receptors and kinins in the cardiopro-
tective effect of angiotensin II type 1 antagonists (AT1-ant) in rats with heart failure (HF)
after myocardial infarction.
BACKGROUND The AT1-ant is as effective as angiotensin-converting enzyme inhibitors in treating HF, but
the mechanisms whereby AT1-ant exert their benefits on HF in vivo are more complex than
previously understood.
METHODS Brown Norway Katholiek rats (BNK), which are deficient in kinins because of a mutation in
the kininogen gene, and their wild-type control (Brown Norway [BN]) underwent myocardial
infarction. Two months later, they were treated for two months with: 1) vehicle; 2) AT1-ant
(L158809, Merck, Rahway, New Jersey); 3) AT1-ant  AT2-ant (PD-123319, Parke Davis,
Ann Arbor, Michigan); or 4) AT1-ant  kinin B2 receptor antagonist (B2-ant) (icatibant)
(only BN). We measured left ventricular weight (LVW) gravimetrically, myocyte cross-
sectional area (MCSA) and interstitial collagen fraction (ICF) histologically, and ejection
fraction by ventriculography.
RESULTS Development of HF was comparable in BN and BNK rats. The AT1-ant reduced LVW and
MCSA and the AT2-ant blocked these effects in BN rats, but the B2-ant did not. The
AT1-ant reduced LVW and MCSA in BNK rats, and this effect was reversed by the AT2-ant.
In BN rats, ICF was reduced and LVEF increased by AT1-ant, and both AT2-ant and B2-ant
reversed these effects. In BNK rats, the AT1-ant failed to reduce ICF, and its therapeutic
effect on LVEF was significantly blunted.
CONCLUSIONS In HF, the AT2 receptor plays an important role in the therapeutic effects of AT1-ant, and
this effect may be mediated partly through kinins; however, kinins appear to play a lesser role
in the antihypertrophic effect of AT1-ant. (J Am Coll Cardiol 2004;43:1473–80) © 2004
by the American College of Cardiology Foundationc
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ayocardial infarction (MI) induces left ventricular (LV)
ilatation associated with myocyte hypertrophy and inter-
titial fibrosis of the noninfarcted myocardium. These
hanges in LV geometry, referred to as remodeling after
I, contribute to the development of heart failure (HF) (1).
ctivation of vasoactive hormones, such as angiotensin,
inins, and nitric oxide, may be an important adaptive
nd/or maladaptive mechanism in the pathophysiology of
F. There is evidence that the renin–angiotensin system is
ctivated in HF. Angiotensin II (Ang II), the key effector
eptide of the renin–angiotensin system, has been impli-
ated in the development of ventricular remodeling through
ts proposed growth-promoting properties, thereby stimu-
ating myocyte hypertrophy and collagen synthesis, which
ead to myocardial dysfunction. Angiotensin II receptors
From the *Hypertension and Vascular Research Division, Department of Internal
edicine and the †Division of Biostatistics and Research Epidemiology, Henry Ford
ospital, Detroit, Michigan. This work was supported by NIH grant HL28982.
Manuscript received August 21, 2003; revised manuscript received November 13,k003, accepted November 25, 2003.omprise two major subtypes, angiotensin II type 1 (AT1)
nd angiotensin II type 2 (AT2) (2). Most known effects of
ng II in the cardiovascular system are mediated by the
T1 receptor. It has been reported that the AT2 receptor is
nvolved in inhibition of cellular differentiation, growth, and
poptosis and may be activated in disease states such as MI
nd cardiac hypertrophy (3–5). Thus, the AT2 receptor
ould play an important role in counterbalancing some of
he effects of Ang II by antagonizing its action on the AT1
eceptor. Angiotensin II type 1 antagonists (AT1-ant) have
een shown to improve cardiac function and remodeling in
F in both clinical and animal studies (6,7). It has been
roposed that the blockade of AT1 receptors increases Ang
I, activating AT2 receptors, which leads to cardioprotection
ither directly or via kinins (8), although their exact physi-
logical or pathophysiological role is not clearly defined.
Kinins, which are potent vasoactive peptides, are released
rom high- and low-molecular-weight kininogens by plasma
nd tissue kallikreins (9). Evidence suggests that a local
allikrein–kinin system exists in the heart, which enables it
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AT2 Receptors and Kinins in Effect of AT1-Ant April 21, 2004:1473–80o synthesize and release kinins (10,11). Kinins act via two
eceptors, B1 and B2, and most of their effects have been
ttributed to the B2 receptor, although recent evidence
uggests that the B1 receptor may also play an important
ole (12–14). Several studies have shown that during acute
yocardial ischemia, release of kinins from the heart is
apidly increased. We have previously reported that blood
ressure and severity of myocardial ischemia-reperfusion
njury in Brown Norway Katholiek (BNK) rats (which are
eficient in kinins because of a mutation in the kininogen
ene) and in B2 kinin receptor knockout (B2-KO) mice
ere no different than their wild-type controls (15); how-
ver, they exhibited a diminished response to ischemic
reconditioning (15). We further reported that in BNK rats
nd in B2-KO with chronic HF due to MI, infarct size and
evelopment of HF were no different than their respective
ontrols; however, the effects of angiotensin-converting
nzyme inhibitors were diminished in BNK rats and B2-KO
ice with HF after MI (16,17). These studies suggest that
lthough kinins may not be important in either cardiac
emodeling or the pathophysiology of HF under basal
onditions, in response to angiotensin-converting enzyme
nhibitors they play an important role in decreasing remod-
ling and improving cardiac function.
In the present work, we tested the hypothesis that in rats
ith HF after MI, the effects of AT1-ant on cardiac
emodeling and LV function are mediated in part by the
T2 receptor. Furthermore, we hypothesized that some of
he effects of the AT2 receptor are mediated by kinins
hereas others are not. To study the role of the AT2 and B2
eceptors, we used an AT2-ant and a B2 receptor antagonist
B2-ant), respectively. To determine the role of kinins, we
sed kinin-deficient BNK rats, expecting that in this strain
hose effects of AT1-ant that are mediated by kinins via both
Abbreviations and Acronyms
Ang II  angiotensin II
AT1  angiotensin II type 1
AT1-ant  angiotensin II type 1 antagonist
AT2  angiotensin II type 2
B2-ant  kinin B2 receptor antagonist
B2-KO  B2 kinin receptor knockout
BN  Brown Norway
BNK  Brown Norway Katholiek
EDV  end-diastolic volume
EF  ejection fraction
ESV  end-systolic volume
HF  heart failure
ICF  interstitial collagen fraction
LV  left ventricular/ventricle
LVW  left ventricular weight
MBP  mean blood pressure
MCSA  myocyte cross-sectional area
MI  myocardial infarction
NO  nitric oxidehe B1 and/or B2 receptors would be decreased or absent,hereas those effects that are mediated by activation of the
T2 receptor independently of kinins should be present.
ATERIAL AND METHODS
ale BNK rats (obtained from the Department of Phar-
acology, Kitasato University School of Medicine, and bred
n our animal care facilities) and Brown Norway (BN) rats
Charles River Laboratories, Wilmington, Massachusetts),
oth weighing 255 to 275 g, were housed in an air-
onditioned room with a 12-h light/dark cycle where they
eceived standard laboratory rat chow (0.4% sodium) and
rank tap water. They were given five to seven days to adjust
o their new environment and were anesthetized with
odium pentobarbital before all surgical procedures (50
g/kg intraperitoneally). This study was approved by the
enry Ford Hospital Institutional Animal Care and Use
ommittee.
xperimental HF model. Coronary artery ligation was
erformed as described previously (18). Rats were intubated
nd ventilated with room air using a positive-pressure
espirator (Model 680, Harvard, South Natick, Massachu-
etts). A left thoracotomy was performed via the fourth
ntercostal space and the lungs retracted to expose the heart.
fter opening the pericardium, the left anterior descending
oronary artery was ligated with a 7-0 silk suture near its
rigin; acute myocardial ischemia was deemed successful
hen the anterior wall of the LV became cyanotic. The
ungs were inflated by increasing positive end-expiratory
ressure, and the thoracotomy site was closed in layers.
nother group of rats underwent sham ligation; the proce-
ure was similar, but the suture was not tightened around
he coronary artery. Our previous study showed that rats
eveloped HF (ejection fraction [EF] 30% to 35%) by two
onths after a large MI (19).
xperimental protocols. Two months after coronary liga-
ion, BN and BNK rats were randomly divided into the
ollowing groups:
. Vehicle: BN (n  11) and BNK (n  17) were treated
with vehicle (tap water) for two months.
. AT1-ant (L158809, Merck): BN (n  17) and BNK
(n  17) were treated for two months with the AT1-ant
(1.5 mg/kg/day) in drinking water. To calculate how
much AT1-ant we should add to the water, we estimated
intake at 20 ml/day.
. AT1-ant  AT2-ant (PD123319, Parke Davis, Ann
Arbor, Michigan): BN (n  6) and BNK (n  5) were
treated with AT1-ant  AT2-ant (10 mg/kg via mini-
osmotic pump).
. AT1-ant  B2-ant (icatibant): BN (n  16) with HF
were treated with AT1-ant  B2-ant (100 g/kg/day via
mini-osmotic pump). We did not use the B2-ant in BNK
because they are deficient in kinins.
. BN and BNK sham ligation: BN (n  10) and BNK
(n  12).
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April 21, 2004:1473–80 AT2 Receptors and Kinins in Effect of AT1-Antardiac hemodynamics and ventriculography. Rats were
nesthetized and a polyethylene catheter (PE-50) inserted
nto the carotid artery. Mean blood pressure (MBP) and
eart rate were measured with a P23XL pressure transducer
onnected to a processor (Gould Brush 220, Cleveland,
hio). The carotid catheter was advanced into the LV and
entriculograms recorded on 35-mm cine film at 60
rames/s during injection of 0.5 ml contrast material (Reno-
-60, Squibb, New Brunswick, New Jersey). The films
ere projected, and the margins of the LV image traced
uring end-diastole and end-systole over three consecutive
ardiac cycles. End-systolic volume (ESV) and end-diastolic
olume (EDV) were determined using the area-length
ethod (20). Left ventricular ejection fraction (EF) was
alculated as: EF  (EDV  ESV)/EDV.
athological and histological examination. After the he-
odynamic and ventriculographic studies, the rats were
illed and the chest opened. The heart was stopped during
iastole by injecting 15% potassium chloride, and then
xcised and weighed and the LV sectioned transversely into
our slices from apex to base. Slices were rapidly frozen in
sopentane solution pre-cooled in liquid nitrogen and used
or morphometric analysis of infarct size and histological
xamination. The histological study only involved the non-
nfarcted myocardium.
etermination of myocardial infarct size. A 6-m sec-
ion from each slice was stained with Masson’s trichrome.
ections from all four slices were projected onto a screen.
nfarct size was determined by Gomori trichome staining
nd expressed as the ratio of the infarcted portion to total
V circumference (21).
etermination of myocyte cross-sectional area (MCSA)
nd interstitial collagen fraction (ICF). Sections were
retreated with 3.3 U/ml neuroaminidase type V (Sigma,
t. Louis, Missouri), then double-stained with: 1)
uorescein-labeled peanut agglutinin (Victor Lab, Burlin-
ame, California) to delineate MCSA and the interstitial
pace; and 2) rhodamine-labeled Griffonia simplicifolia lectin
to show only the capillaries. From each slice, four radially
riented microscopic fields were selected at random and
hotographed at a magnification of 400 times. Myocyte
ross-sectional area was measured by computer-based
lanimetry (Jandel Scientific, Corte Madera, California),
CF was calculated as total interstitial space minus total
apillary area, and MCSA and ICF from all photographs
ere averaged (8).
ata analysis. All data are expressed as mean  SEM.
tudent’s t test was used to compare mean values of the
arious parameters (left ventricular weight [LVW], MCSA,
CF, infarct size, MBP, LVEF, LVEDV, and LVESV)
mong different groups, specifically, sham versus HF-
ehicle, HF-vehicle versus HF-AT1-ant, HF-AT1-ant ver-
us HF-AT1-ant  AT2-ant, and HF-AT1-ant versus
F-AT1-ant  B2-ant in BN and BNK rats. Hochberg’s
ethod for multiple comparisons was used to adjust thelpha level of significance (22). Effects of AT1-ant treat- tent in the two types of rats (BN and BNK) were compared
sing two-way analysis of variance, as were differences from
F-vehicle to HF-AT1-ant between BN and BNK. A test
or interaction was used between group and strain. A
ignificant result would indicate that the effect observed
etween groups is dependent upon the strain.
ESULTS
f the 52 BN rats that underwent left anterior descending
oronary artery ligation, 1 died after surgery, for a mortality
ate of 2%. In addition, one of the BN rats in the
F-vehicle group died within three months. Of the 41
NK rats that underwent coronary ligation, 2 of those in
he HF-vehicle group died within three months after MI.
o rats in the sham-ligated group died.
nfarct size. Infarct size was similar in all groups (Table 1).
ll rats with coronary ligation developed a large MI,
anging from 40% to 45% of the LV circumference.
eart weight, MCSA and ICF in BN and BNK rats
uring the development of HF. Left ventricular weight,
CSA, and ICF were similar in sham-ligated BN and
NK rats. Left ventricular weight, ICF, MCSA, LVEDV,
nd LVESV increased, and LVEF decreased similarly in the
F-vehicle group in both strains (Fig. 1). Thus, both BN
nd BNK rats developed similar remodeling and HF after
I.
ffect of AT1-ant and B2-ant on heart weight, MCSA,
nd ICF in BN and BNK rats. In BN rats, the AT1-ant
ignificantly reduced LVW (p  0.001 vs. HF-vehicle) and
CSA (p  0.001 vs. HF-vehicle), while the AT2-ant
eversed these effects. In BNK rats, the AT1-ant also
ecreased LVW (p  0.05 vs. HF-vehicle) and MCSA (p
0.001 vs. HF-vehicle) and, again, the AT2-ant blocked
hese effects (p  0.05 vs. HF-AT1-ant) (Fig. 2). In BN
ats, the B2-ant did not reverse the effect of the AT1-ant on
ither LVW or MCSA. Although these effects seemed less
vident in BNK than in BN, the differences were not
tatistically significant (Fig. 3). These data on LVW and
CSA suggest that AT2 receptors play an important role in
he antihypertrophic effect of AT1-ant in rats with HF and
hat this effect is independent of kinins.
In BN rats, the AT1-ant significantly decreased ICF (p
.01 vs. HF-vehicle), and this decrease was reversed by both
T2-ant (p  0.001) and B2-ant (p  0.001). In BNK rats,
he AT1-ant did not significantly decrease ICF, and the
T2-ant had no effect (Fig. 2). The decrease in ICF was
ignificantly greater in BN than in BNK rats (Fig. 3). These
esults suggest that the antifibrotic effect of the AT1-ant was
artly mediated by kinins via the B2 receptor.
emodynamics and cardiac function during the devel-
pment of HF. Sham-ligated BN and BNK exhibited no
ignificant differences in MBP, LVEDV, LVESV, or
VEF. In both HF-vehicle groups LVEDV and LVESV
ere increased and MBP and LVEF were decreased, buthese changes were similar in both strains (Table 1, Fig. 1).
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AT2 Receptors and Kinins in Effect of AT1-Ant April 21, 2004:1473–80ffect of AT1-ant and B2-ant on MBP, LVEDV,
VESV, and LVEF. The AT1-ant reduced MBP in both
trains (BN: p  0.01; BNK: p  0.001 vs. HF-vehicle). In
N rats, the AT1-ant significantly decreased EDV (p 
.01) and ESV (p  0.001) and increased LVEF (p 
.001) compared with HF-vehicle, while the AT2-ant
eversed these effects (Fig. 2). The B2-ant partially but
ignificantly reversed the effect of ESV (p  0.01) and EF
p  0.001) and marginally reversed the effects of the
T1-ant on LVEDV (p  0.05) (Fig. 4). In BNK rats, the
T1-ant caused a very small decrease in LVEDV (p 
.05), and the same was true of LVEF (p  0.05). Changes
n LVESV and LVEF were much smaller in BNK than in
N rats (Fig. 4, right panel), and the AT2-ant had no effect
Fig. 2). These data suggest that the AT2 receptor partici-
ates significantly in the beneficial effects of AT1-ant, which
re mediated to some extent by kinins.
ISCUSSION
e found that in rats genetically deficient in kininogen, the
recursor of kinins, basal cardiac hemodynamics and func-
ion, as well as morphology and histology, were no different
rom rats with an intact kallikrein–kinin system. Kinin
eficiency did not aggravate cardiac remodeling after MI;
ndeed, infarct size, as well as LV hypertrophy, ICF,
VEDV, LVESV, and LVEF, were all similar in both
ininogen-deficient BNK rats and BN rats with normal
ininogen, suggesting that either kinins do not play a major
ole in the regulation of cardiac structure and function or
hat BNK rats have developed a compensatory mechanism
o overcome the lack of circulating kinins. We further
etermined that the AT2 receptor participates in the ther-
peutic effects of AT1-ant because its effects were blocked
y the AT2-ant. Kinins and the B2 receptor were found to
articipate in some but not all of the cardioprotective effects
f the AT1-ant because the decreased ICF and improved
VEF, EDV, and ESV caused by the AT1-ant were
locked by the B2-ant in BN rats and entirely absent in
NK rats. Collectively, these data suggest that the beneficial
ardiac effects of AT1-ant on HF are mediated at least in
art by the AT2 receptor via kinins.
Our data demonstrated that the decrease in heart weight
aused by AT1-ant was greater in BN than in BNK rats
BN: 60 mg/100 g body weight; BNK: 23 mg/100 g
ody weight; p  0.05). Also, the AT1-ant decreased both
VW and MCSA in BNK rats; however, these changes,
lthough statistically significant, tended to be smaller than
n BN rats. Furthermore, the antihypertrophic effects ob-
erved in BN rats were blocked by the AT2-ant but not by
he B2-ant. We have previously found that in Lewis rats
ith HF due to MI, the B2-ant did not block the antihy-
ertrophic effect of the AT1-ant (8). Similarly, in B2-KO
ice with HF after MI, we found that the AT1-ant
ecreased LV weight, MCSA, and LV mass, although the
last of these decreases was less pronounced in B2-KO miceT B M H I H R E h
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April 21, 2004:1473–80 AT2 Receptors and Kinins in Effect of AT1-Anthan in their wild-type controls. Taken together, these data
uggest that most of the antihypertrophic effects of AT1-ant
re not mediated by kinins.
Finally, we found that the effects of AT1-ant are inde-
igure 1. Left ventricular weight (LVW), myocyte cross-sectional area (M
LVEDV), left ventricular end-systolic volume (LVESV), and left ventricu
n Brown Norway (BN) and Brown Norway Katholiek (BNK) rats. ***p 
igure 2. Effect of the AT1-ant L158809 (AT1a) alone and combined with
he AT2-ant PD123319 (AT2a) on LVW, MCSA, ICF, LVEDV, LVESV,
nd LVEF in BN and BNK rats with HF after myocardial infarction.
p  0.05; **p  0.01; ***p  0.001. Abbreviations as in Figure 1. *endent of the reduction in blood pressure; although its
ffects on cardiac function and remodeling were accompa-
ied by a reduction in MBP, the AT2-ant or kinin antag-
), interstitial collagen fraction (ICF), left ventricular end-diastolic volume
ction fraction (LVEF) four months after sham or coronary artery ligation
1. HF  heart failure.
igure 3. Effect of the AT1-ant L158809 (AT1a) alone and combined with
he kinin B2-ant icatibant (B2) on LVW, MCSA, and ICF. Right panels
how the difference in the response to AT1-ant ( from HF vehicle) between
N and BNK rats with HF after myocardial infarction. *p  0.05;CSA
lar eje*p  0.01; ***p  0.001. Abbreviations as in Figure 1.
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AT2 Receptors and Kinins in Effect of AT1-Ant April 21, 2004:1473–80nist blocked these beneficial effects but not the changes in
BP. In BNK rats, AT1-ant decreased MBP as well but
ad no effect on function or cardiac remodeling. Thus, these
ata suggest that the cardioprotective effects of AT1-ant in
F are independent of its effect on blood pressure reduc-
ion. Collectively, the present data support the hypothesis
hat when the AT1 receptor is blocked, activation of the
T2 receptor contributes to the cardiac therapeutic effects
f AT1-ant and, moreover, that the AT2 receptor may act
ia two different mechanisms, one that is mediated by kinins
nd another that is not (Fig. 5).
There is now convincing evidence that AT1-ant are
ffective in the treatment of HF (8,23). The mechanisms by
hich AT1-ant exert their beneficial effects on HF in vivo
re more complex than previously understood. Clearly,
T1-ant prevent the effects of Ang II on the AT1 receptor,
nd this antihypertensive effect may lead to cardioprotection
24); however, evidence is accumulating that the AT2
eceptor also plays an important role in the therapeutic
ffects of AT1-ant. AT2 receptors are expressed at low
oncentrations in normal cardiac myocytes but become
pregulated in pathological states (3,5,25). It has been
uggested that AT2-ant may counterbalance the effects of
T1-ant on cell growth and proliferation (26–28). Re-
ently, Yang et al. (29) reported that overexpression of the
igure 4. Effect of the AT1a alone and combined with the kinin B2ant on
VEDV, LVESV, and LVEF. Right panels show the difference in the
esponse to AT1-ant ( from HF vehicle) in BN and BNK rats with HF
fter myocardial infarction. *p  0.05; **p  0.01; ***p  0.001.
bbreviations as in Figure 1.ardiac AT2 receptor improves baseline LV systolic function snd preserves function during remodeling after MI. We
ave recently shown that cardiac hemodynamic, functional,
nd histological phenotypes are similar between AT2
nockouts and wild-type mice under basal conditions and
uring the development of HF; however, the benefits of
T1-ant are attenuated in AT2-KO mice, suggesting that
T2 receptors are not essential for regulation of cardiac
unction and morphology, whereas they play a significant
ole in the therapeutic effect of AT1-ant (30). Our data from
N rats in the present study show that AT1-ant improved
ardiac function and attenuated interstitial fibrosis, hyper-
rophy, and LV volume, while AT2-ant blocked these
rotective effects, indicating that AT2 receptors mediate the
ardioprotective effect of AT1-ant.
Brown Norway Katholiek rats are a substrain of BN rats
ith a spontaneous genetic mutation that impairs transpor-
ation of kininogen out of the cells where kinins are released
rom high- and low-molecular-weight kininogens by plasma
nd tissue kininogenases such as kallikreins (9,31). Evidence
uggests that a local kallikrein–kinin system exists in the
eart that enables it to synthesize and release kinins
10,11,32). Kinins act via two subtypes of G-protein–
oupled receptors, B1 and B2 (33). B2 receptors are consti-
utively expressed in most tissues and are responsible for
ost known effects of kinins (34); in addition, they are
pecifically inhibited by the B2-ant icatibant. The B1 recep-
or is only weakly expressed under physiological conditions
ut is strongly induced under pathological conditions, such
s inflammation or tissue damage (35). Recent evidence
igure 5. Hypothetical mechanism of action of AT1-ant in heart failure: 1)
T1-ant prevent the effect of angiotensin II on the AT1 receptor, leading
o cardioprotection (preventing cardiac hypertrophy, fibrosis, and remod-
ling and improving function); 2) angiotensin II activates the AT2
eceptors, which act via release of kinins, and B2 and/or B1 receptors, which
ct via release of nitric oxide, thereby leading to anticardiac fibrosis,
reventing remodeling and improving function; a) in BN rats with HF,
2-ant only blocks the B2 receptor; the B1 receptors may be activated and
revent cardiac hypertrophy; and b) in BNK rats neither B1 nor B2
eceptors are activated; as circulating kinins are absent in this strain, and
T2 receptors may act directly via nitric oxide to prevent cardiac hyper-
rophy. Rectangular callouts (AT1-ant, AT2-ant or B2-ant) point to the
eceptor blockade site, and oval callouts point to two strains (BN and
NK). Abbreviations as in Figure 1.uggests that the B1 receptor may also play an important
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sing a B2-ant or B2-KO mice, we speculated that in such
ases kinins might act via the B1 receptor. However, in
NK rats neither the B1 nor B2 receptor is activated because
irculating kinins are absent in this strain.
Kinins appear to play an important role in some of the
herapeutic effects of the AT1-ant. The data in the present
ork with B2-ant and in BNK demonstrate that the effects
f AT1-ant on fibrosis, LVEDV, LVESV, and LVEF were
lunted by the B2-ant and absent in BNK rats, suggesting
hat the benefits of AT1-ant are partly mediated by the AT2
eceptor via kinins. In support of this hypothesis, Seyedi et
l (36) showed in vitro that activation of AT2 during
lockade of AT1 stimulated the release of autacoids such as
rostaglandin E2 and nitric oxide (NO) either directly and/or
ia stimulation of kinins. Tsutsumi et al. (37) reported that in
ortas from mice with overexpression of the AT2 receptor
ene, Ang II caused a significant increase in kininogenase
ctivity and cyclic guanidine monophosphate production,
hich was further enhanced by an AT1-ant but blocked by an
T2-ant, kinin antagonist, or NO synthase inhibitor. These
ndings suggest that AT2 activation stimulates kinin release,
hich further promotes NO/cyclic guanidine monophosphate
roduction in a paracrine manner and thus potentiates vaso-
ilation and regional blood flow regulation. Furthermore, we
ecently demonstrated that the therapeutic effect of AT1-ant
n cardiac function and remodeling after MI was diminished
n B2 and endothelial nitric oxide synthase knockout mice,
roviding further in vivo evidence that kinins and
ndothelium-derived NO play an important role in the bene-
cial cardiac effect of AT1-ant (17,38).
In summary, using BN and BNK rats with HF after MI,
e have demonstrated that the cardioprotective effect of
T1-ant is mediated by AT2 receptors, which exert their
ctions (antifibrosis, function, and geometry) partially
hrough kinins. Kinins play a lesser role in the antihyper-
rophic effect of AT1-ant.
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